Slide 1: Exchange filing cover letter: Presentation – Q2 FY26 Earnings Call
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/TG/2025-26/118 November 12, 2025 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of
Slide 2: Biocon Limited Q2 FY26 Earnings Call
Biocon Limited Q2 FY26 Earnings Call 12 - NOVEMBER- 2 0 2 5
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Chairperson Opening Remarks
Chairperson Opening Remarks
Slide 5: Opening Remarks: Q2 FY26 Performance Overview
Opening Remarks: Q2 FY26 Performance Overview Biosimilars and Generics businesses delivered double-digit Y-o-Y growth, CRDMO business performance in-line with plan Strengthened our balance sheet by settling structured debt obligations with Goldman Sachs & Kotak from the QIP proceeds and executing an
Slide 6: Q2 FY26 Financial Highlights
Q2 FY26 Financial Highlights
Slide 7: Financial Highlights – Q2 FY26
Financial Highlights – Q2 FY26 In ₹ Cr Q2 FY26 Q2 FY25 Q1 FY26 YoY% QoQ% Generics 774 624 697 24 11 Biosimilars 2,721 2,182 2,458 25 11 CRDMO 911 891 875 2 4 Revenue from Operations 4,296 3,590 3,942 20 9 Total Revenue 4,389 3,623 4,022 21 9 Core EBITDA1 1,218 992 1,090 23 12 % Margin 28 28 27 R&D (
Slide 8: Biosimilars
/ 7; od { Vids bh | / ee - i; Z HU //f I MEE
Slide 9: Biocon Biologics: Q2 FY26 Business Performance update
Biocon Biologics: Q2 FY26 Business Performance update North America Highlights • Yesintek gained strong commercial traction with a market leading position Q2 Q2 Q1 QoQ In ₹ Cr YoY% • Our oncology portfolio continued to deliver strong performance FY26 FY25 FY26 % • Entered in a pioneering partnership
Slide 10: Generics
Generics
Slide 11: Biocon Generics: Q2 FY26 Business Performance update
Biocon Generics: Q2 FY26 Business Performance update Strong revenue performance in Q2FY26, with growth on both Y-o-Y, as Q2 Q2 Q1 In ₹ Cr YoY% QoQ% well as on a sequential basis FY26 FY25 FY26 Growth supported by recent product launches in generic formulations Segment 774 624 697 24 11 in the US and
Slide 12: CRDMO
CRDMO
Slide 13: CRDMO: Q2 FY26 Business Performance update
CRDMO: Q2 FY26 Business Performance update Performance in Q2 was in line with plan with revenue up 2% YOY; 4% Q2 Q2 Q1 sequentially In ₹ Cr YoY% QoQ% FY26 FY25 FY26 Quarterly performance driven by revenue growth from research services, Segment 911 891 875 2 4 offsetting the expected inventory correc
Slide 14: Concluding Remarks
Concluding Remarks
Slide 15: Concluding Remarks: Q2 FY26
Concluding Remarks: Q2 FY26 Strong and sustained momentum across our Biologics business • Balance sheet is stronger, expect continued improvement in profitability in the quarters ahead • Our expanding biosimilar portfolio is differentiated, focused on high-value, high growth therapy areas • Our inte
Slide 16: Accelerating Reach
ACCELERATING REACH EXPANDING ACCESS PROPELLING GROWTH